Q-omics provides the consensus-scored INO80E profile across patient tissues and cancer cell-line models. INO80E expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, INO80E is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, INO80E RNA expression shows 19,046 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where INO80E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INO80E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INO80E survival associations across molecular data types. INO80E RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INO80E RNA expression–survival associations across cancer types. High INO80E expression shows unfavorable associations in ACC, UVM, COAD, LGG, SKCM and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for INO80E RNA expression.
This table summarizes INO80E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for INO80E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INO80E shows higher tumor expression in KIRC, KIRP, COAD, HNSC, LIHC and STAD. The KIRC box plot shows higher INO80E RNA expression in tumor versus normal tissue (log2 FC = +0.940, t-test p < 0.001).
This table shows molecular features associated with INO80E in patient tissues and cancer cell lines. In patient samples, INO80E shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, INO80E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
